alexa Phenotype Breath Tests as Companion Diagnostic Tests (CDx) in Clinical Trials of Drugs

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Phenotype Breath Tests as Companion Diagnostic Tests (CDx) in Clinical Trials of Drugs

The emerging field of personalized medicine will require a change in the traditional paradigm of “one drug fits all” in prescribing drugs. The commercial success of new drugs coming to the healthcare field will depend on utilizing differential diagnostic tests and/or companion biomarker assays to identify patients who are responders or non responders. This major market trend will force pharmaceutical and biotechnology companies to adopt the use of biomarker diagnostic tests in the drug development process. Companion diagnostic tests (CDx) are assays intended to enable physicians in the selection of right therapy for the patient at the optimal dose for the highest efficacy and minimal toxicity thereby lowering healthcare costs.

 

Citation: Modak AS (2012) Phenotype Breath Tests as Companion Diagnostic Tests (CDx) in Clinical Trials of Drugs. J Pharmacogenomics Pharmacoproteomics 3:e106. doi: 10.4172/2153-0645.1000e106

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger